Related Experiment Video
Updated: May 7, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
[Genetic Mutation Profile and Risk Stratification of Cytogenetically Normal Acute Myeloid Leukemia with Mutations
Lei-Ming Cao1, Ming-Yue Liao1, Ya-Lan Zhou1
1Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University,Beijing 100044, China.
Adults with cytogenetically normal acute myeloid leukemia (CN-AML) and CEBPA-bZIP mutations have complex co-mutations. A nomogram model identifies high-risk patients who benefit from allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Context:
- Cytogenetically normal acute myeloid leukemia (CN-AML) with CEBPA-bZIP mutations represents a distinct subset of adult AML.
- Understanding the gene mutation profile and prognostic significance is crucial for optimizing treatment strategies in this patient group.
Purpose:
- To evaluate the gene mutation profile and prognostic significance of adult CN-AML with CEBPA-bZIP mutations.
- To develop a nomogram model for risk stratification and guide post-remission therapy decisions.
Summary:
- Targeted sequencing of 141 adult CN-AML patients with CEBPA-bZIP mutations identified a complex co-mutation pattern.
- A nomogram model incorporating WBC count, CSF3R, KMT2A, and DNA methylation-related gene mutations stratified patients into low- and high-risk groups.
- High-risk patients demonstrated significantly improved leukemia-free survival and overall survival with allogeneic hematopoietic stem cell transplantation (allo-HSCT) compared to maintenance chemotherapy.
Impact:
- The developed nomogram model provides a valuable tool for prognosis estimation and treatment decision-making in adult CN-AML with CEBPA-bZIP mutations.
- Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended as post-remission therapy for high-risk individuals identified by the nomogram.
Related Concept Videos
Mutagenicity and Carcinogenicity
Mutations

